Vor Biopharma (NASDAQ:VOR) Major Shareholder Sells $1,269,243.51 in Stock

Vor Biopharma Inc. (NASDAQ:VOR) major shareholder Reprogrammed Interchange Llc sold 40,983 shares of the business’s stock in a transaction on Friday, October 10th. The stock was sold at an average price of $30.97, for a total transaction of $1,269,243.51. Following the completion of the sale, the insider owned 1,333,792 shares in the company, valued at approximately $41,307,538.24. The trade was a 2.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Thursday, October 16th, Reprogrammed Interchange Llc sold 2,021 shares of Vor Biopharma stock. The stock was sold at an average price of $30.45, for a total transaction of $61,539.45.
• On Wednesday, October 15th, Reprogrammed Interchange Llc sold 71,655 shares of Vor Biopharma stock. The stock was sold at an average price of $31.92, for a total transaction of $2,287,227.60.
• On Tuesday, October 14th, Reprogrammed Interchange Llc sold 33,668 shares of Vor Biopharma stock. The stock was sold at an average price of $30.32, for a total transaction of $1,020,813.76.
• On Monday, October 13th, Reprogrammed Interchange Llc sold 22,006 shares of Vor Biopharma stock. The stock was sold at an average price of $32.44, for a total transaction of $713,874.64.
• On Thursday, October 9th, Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma stock. The stock was sold at an average price of $32.07, for a total transaction of $1,567,709.88.
• On Wednesday, October 8th, Reprogrammed Interchange Llc sold 75,262 shares of Vor Biopharma stock. The stock was sold at an average price of $33.87, for a total transaction of $2,549,123.94.
• On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The stock was sold at an average price of $33.84, for a total transaction of $934,796.16.
• On Monday, October 6th, Reprogrammed Interchange Llc sold 70,763 shares of Vor Biopharma stock. The stock was sold at an average price of $37.01, for a total transaction of $2,618,938.63.
• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The stock was sold at an average price of $37.83, for a total transaction of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The stock was sold at an average price of $39.83, for a total transaction of $1,292,523.33.

Vor Biopharma Stock Performance

Shares of VOR stock opened at $29.00 on Friday. The business has a fifty day moving average of $36.55. The stock has a market cap of $198.65 million, a PE ratio of -0.11 and a beta of 2.07. Vor Biopharma Inc. has a 52 week low of $2.62 and a 52 week high of $65.80.

Vor Biopharma (NASDAQ:VOR) last announced its earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Hedge Funds Weigh In On Vor Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of VOR. Money Concepts Capital Corp boosted its stake in shares of Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after purchasing an additional 26,535 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares during the last quarter. XTX Topco Ltd purchased a new stake in Vor Biopharma during the second quarter valued at approximately $66,000. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma during the first quarter valued at approximately $100,000. Finally, Jane Street Group LLC purchased a new stake in Vor Biopharma during the first quarter valued at approximately $140,000. 97.29% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on VOR. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research report on Wednesday, September 24th. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Vor Biopharma in a research report on Thursday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. Zacks Research cut shares of Vor Biopharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. Finally, Wall Street Zen downgraded shares of Vor Biopharma to a “strong sell” rating in a research note on Saturday, June 28th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $77.83.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.